Evaluation of a smartphone app for patients with panic disorder with or without comorbid agoraphobia

Phase 4

• Conditions: F41.0; F40.01; F40.00; Panic disorder [episodic paroxysmal anxiety]

• Registration Number: DRKS00029090
• Lead Sponsor: Mindable Health GmbH

Brief Summary

Analyses confirmed significant group x time interaction effects for primary outcome (panic- and agoraphobia symptoms), and for one of the secondary outcomes (anxiety control). There were no effects for quality of life or impairment.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-10
• Study Completion: 2022-11-11
• Results First Posted: 2024-07-16
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 107

Inclusion Criteria

One of the following diagnoses: F41.0, F40.00, F40.01; informed consent; Minimum age of 18 years

Exclusion Criteria

no smartphone; intake of benzodiazepines; initiation or changes in a psychopharmacotherapy during the last 2 months; komorbid psychotic disorder; komorbid substance use disorder; comorbid chronic cardiovascular or pneumological disorders; acute suicidality; ongoing psychotherapeutic treatment; not fluid in German language

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Post-Assessment 8 weeks after study intake<br>primary outcomes:<br>anxiety symptoms: Panic- and Agoraphobia-Scale (PAS), questionnaire<br>quality of life: WHO-quality of life scale (WHOQOL-BREF), questionnaire<br>perceived control: Anxiety Control Questionnaire (ACQ); questionnaire

Secondary Outcome Measures

Name	Time	Method
Agoraphobic Cognitions Questionnaire, Bodily Sensations Questionnaire (Chambless et al., 1984)<br>Beck Depression Inventory II (Beck et al., 1996)<br>Brief Symptom Inventory (Derogatis, 1992)